Coronary artery disease and diabetes mellitus

Cardiology Clinics

Volumn 32, Issue 3, 2014, Pages 439-455

  Aronson, Doron ^a   Edelman, Elazer R ^b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blood glucose; Coronary disease; Diabetes mellitus; Hypoglycemic agents; Revascularization; Statins

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALOGLIPTIN; ALPHA GLUCOSIDASE INHIBITOR; ATORVASTATIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EVEROLIMUS; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEGLITINIDE; METFORMIN; PRAMLINTIDE; PRAVASTATIN; ROSIGLITAZONE; ROSUVASTATIN; SIMVASTATIN; SULFONYLUREA; ANTIDIABETIC AGENT;

BARE METAL STENT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG ELUTING STENT; DRUG SAFETY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; GRAFT PATENCY; HEART DEATH; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPERLIPIDEMIA; HYPOGLYCEMIA; INTERMETHOD COMPARISON; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; STENT THROMBOSIS; GLYCEMIC INDEX; HEALTH; INCIDENCE; PREVALENCE;

CORONARY ARTERY DISEASE; DIABETES MELLITUS; GLOBAL HEALTH; GLYCEMIC INDEX; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MYOCARDIAL REVASCULARIZATION; PREVALENCE; RISK FACTORS;

EID: 84905243632     PISSN: 07338651     EISSN: 15582264     Source Type: Journal    
DOI: 10.1016/j.ccl.2014.04.001     Document Type: Review

References (119)

1. Danaei G., Finucane M.M., Lu Y., et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. Lancet 2011, 378:31-40.
2. Go A.S., Mozaffarian D., Roger V.L., et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014, 129:e28-e292.
3. Schramm T.K., Gislason G.H., Kober L., et al. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk: a population study of 3.3 million people. Circulation 2008, 117:1945-1954.
4. Preis S.R., Pencina M.J., Hwang S.J., et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation 2009, 120:212-220.
5. Berry C., Tardif J.C., Bourassa M.G. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. JAm Coll Cardiol 2007, 49:643-656.
6. Aronson D., Rayfield E.J., Chesebro J.H. Mechanisms determining course and outcome of diabetic patients who have had acute myocardial infarction. Ann Intern Med 1997, 126:296-306.
7. Donahoe S.M., Stewart G.C., McCabe C.H., et al. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775.
8. Aronson D., Bloomgarden Z., Rayfield E.J. Potential mechanisms promoting restenosis in diabetic patients. JAm Coll Cardiol 1996, 27:528-535.
9. Iakovou I., Schmidt T., Bonizzoni E., et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005, 293:2126-2130.
10. Haffner S.M., Lehto S., Ronnemaa T., et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. NEngl J Med 1998, 339:229-234.
11. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. NEngl J Med 2008, 358:2545-2559.
12. Preis S.R., Hwang S.J., Coady S., et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation 2009, 119:1728-1735.
13. Advance Collaborative Group, Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med 2008, 358:2560-2572.
14. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. NEngl J Med 2009, 360:129-139.
15. Currie C.J., Peters J.R., Tynan A., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
16. Dluhy R.G., McMahon G.T. Intensive glycemic control in the ACCORD and ADVANCE trials. NEngl J Med 2008, 358:2630-2633.
17. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009, 119:351-357.
18. Sue Kirkman M., Briscoe V.J., Clark N., et al. Diabetes in older adults: a consensus report. JAm Geriatr Soc 2012, 60:2342-2356.
19. Inzucchi S.E., Bergenstal R.M., Buse J.B., et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35:1364-1379.
20. Bennett W.L., Maruthur N.M., Singh S., et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med 2011, 154:602-613.
21. Hiatt W.R., Kaul S., Smith R.J. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. NEngl J Med 2013, 369:1285-1287.
22. Meinert C.L., Knatterud G.L., Prout T.E., et al. Astudy of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. Diabetes 1970, 19(Suppl):789-830.
23. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. NEngl J Med 2007, 356:2457-2471.
24. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009, 373:2125-2135.
25. Food and Drug Administration. Guidance for industry: diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. 2008. Available at:. Accessed May 19, 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf.
26. Frye R.L., August P., Brooks M.M., et al. Arandomized trial of therapies for type 2 diabetes and coronary artery disease. NEngl J Med 2009, 360:2503-2515.
27. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009, 32:193-203.
28. Nikolaidis L.A., Mankad S., Sokos G.G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004, 109:962-965.
29. Sokos G.G., Bolukoglu H., German J., et al. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am J Cardiol 2007, 100:824-829.
30. Scirica B.M., Bhatt D.L., Braunwald E., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. NEngl J Med 2013, 369:1317-1326.
31. White W.B., Cannon C.P., Heller S.R., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. NEngl J Med 2013, 369:1327-1335.
32. Bianchi C., Miccoli R., Daniele G., et al. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes. Diabetes Care 2009, 32(Suppl 2):S342-S348.
33. Cryer P.E. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care 2012, 35:1814-1816.
34. Bonds D.E., Miller M.E., Bergenstal R.M., et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010, 340:b4909.
35. Zoungas S., Patel A., Chalmers J., et al. Severe hypoglycemia and risks of vascular events and death. NEngl J Med 2010, 363:1410-1418.
36. Frier B.M., Schernthaner G., Heller S.R. Hypoglycemia and cardiovascular risks. Diabetes Care 2011, 34(Suppl 2):S132-S137.
37. Desouza C., Salazar H., Cheong B., et al. Association of hypoglycemia and cardiac ischemia: a study based on continuous monitoring. Diabetes Care 2003, 26:1485-1489.
38. Yakubovich N., Gerstein H.C. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation 2011, 123:342-348.
39. Pinto D.S., Skolnick A.H., Kirtane A.J., et al. U-shaped relationship of blood glucose with adverse outcomes among patients with ST-segment elevation myocardial infarction. JAm Coll Cardiol 2005, 46:178-180.
40. Kosiborod M., Rathore S.S., Inzucchi S.E., et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. Circulation 2005, 111:3078-3086.
41. Rana O., Byrne C.D., Kerr D., et al. Acute hypoglycemia decreases myocardial blood flow reserve in patients with type 1 diabetes mellitus and in healthy humans. Circulation 2011, 124:1548-1556.
42. Libby P., Maroko P.R., Braunwald E. The effect of hypoglycemia on myocardial ischemic injury during acute experimental coronary artery occlusion. Circulation 1975, 51:621-626.
43. Kosiborod M., Inzucchi S.E., Goyal A., et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. JAMA 2009, 301:1556-1564.
44. Gandhi G.Y., Nuttall G.A., Abel M.D., et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. Ann Intern Med 2007, 146:233-243.
45. Griesdale D.E., de Souza R.J., van Dam R.M., et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ 2009, 180:821-827. [discussion: 799-800].
46. D'Ancona G., Bertuzzi F., Sacchi L., et al. Iatrogenic hypoglycemia secondary to tight glucose control is an independent determinant for mortality and cardiac morbidity. Eur J Cardiothorac Surg 2011, 40:360-366.
47. Moghissi E.S., Korytkowski M.T., DiNardo M., et al. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. Diabetes Care 2009, 32:1119-1131.
48. Qaseem A., Humphrey L.L., Chou R., et al. Use of intensive insulin therapy for the management of glycemic control in hospitalized patients: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2011, 154:260-267.
49. Deedwania P., Kosiborod M., Barrett E., et al. Hyperglycemia and acute coronary syndrome: a scientific statement from the American Heart Association Diabetes Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2008, 117:1610-1619.
50. Kearney P.M., Blackwell L., Collins R., et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008, 371:117-125. Cholesterol Treatment Trialists Collaborators.
51. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
52. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists Collaborators.
53. Stone N.J., Robinson J., Lichtenstein A.H., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2013, Available at:, Accessed May 19, 2014. http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a.short.
54. American Diabetes Association Standards of medical care in diabetes-2014. Diabetes Care 2014, 37(Suppl 1):S14-S80.
55. Sattar N., Preiss D., Murray H.M., et al. Statins and risk of incident diabetes: a collaborative meta-analysis ofrandomised statin trials. Lancet 2010, 375:735-742.
56. Preiss D., Seshasai S.R., Welsh P., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
57. United States Food and Drug Administration. DA Drug Safety Communication: Important safety label changes to cholesterol lowering statin drugs. 2012. Available at:. Accessed May 19, 2014. http://www.fda.gov/Drugs/DrugSafety/ucm293101.htm.
58. Ridker P.M., Pradhan A., MacFadyen J.G., et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
59. Dagenais G.R., Lu J., Faxon D.P., et al. Prognostic impact of the presence and absence of angina on mortality and cardiovascular outcomes in patients with type 2 diabetes and stable coronary artery disease: results from the BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) trial. JAm Coll Cardiol 2013, 61:702-711.
60. Armstrong E.J., Rutledge J.C., Rogers J.H. Coronary artery revascularization in patients with diabetes mellitus. Circulation 2013, 128:1675-1685.
61. Dagenais G.R., Lu J., Faxon D.P., et al. Effects of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularizations in patients with type 2 diabetes mellitus and stable ischemic heart disease. Circulation 2011, 123:1492-1500.
62. Maron D.J., Boden W.E., Spertus J.A., et al. Impact of metabolic syndrome and diabetes on prognosis and outcomes with early percutaneous coronary intervention in the COURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation) trial. JAm Coll Cardiol 2011, 58:131-137.
63. King S.B. Is surgery preferred for the diabetic with multivessel disease? Surgery is preferred for the diabetic with multivessel disease. Circulation 2005, 112:1500-1507. [discussion: 1514-5].
64. Legrand V. Therapy insight: diabetes and drug-eluting stents. Nat Clin Pract Cardiovasc Med 2007, 4:143-150.
65. Stenestrand U., James S.K., Lindback J., et al. Safety and efficacy of drug-eluting vs. bare metal stents inpatients with diabetes mellitus: long-term of follow-up in the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J 2010, 31(2):177-186.
66. Stone G.W., Kedhi E., Kereiakes D.J., et al. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus. Circulation 2011, 124:893-900.
67. Silber S., Serruys P.W., Leon M.B., et al. Clinical outcome of patients with and without diabetes mellitus after percutaneous coronary intervention with the resolute zotarolimus-eluting stent: 2-year results from the prospectively pooled analysis of the international global RESOLUTE program. JACC Cardiovasc Interv 2013, 6:357-368.
68. Windecker S., Meier B. Late coronary stent thrombosis. Circulation 2007, 116:1952-1965.
69. Kimura T., Morimoto T., Nakagawa Y., et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: five-year outcome of the j-Cypher Registry. Circulation 2012, 125:584-591.
70. Pfisterer M.E. Late stent thrombosis after drug-eluting stent implantation for acute myocardial infarction: a new red flag is raised. Circulation 2008, 118:1117-1119.
71. Urban P., Gershlick A.H., Guagliumi G., et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006, 113:1434-1441.
72. Machecourt J., Danchin N., Lablanche J.M., et al. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry. JAm Coll Cardiol 2007, 50:501-508.
73. Aoki J., Lansky A.J., Mehran R., et al. Early stent thrombosis in patients with acute coronary syndromes treated with drug-eluting and bare metal stents: the Acute Catheterization and Urgent Intervention Triage Strategy trial. Circulation 2009, 119:687-698.
74. Wiviott S.D., Braunwald E., Angiolillo D.J., et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 2008, 118:1626-1636.
75. Dangas G.D., Caixeta A., Mehran R., et al. Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011, 123:1745-1756.
76. Wenaweser P., Daemen J., Zwahlen M., et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. JAm Coll Cardiol 2008, 52:1134-1140.
77. Lagerqvist B., Carlsson J., Frobert O., et al. Stent thrombosis in Sweden: a report from the Swedish coronary angiography and angioplasty registry. Circ Cardiovasc Interv 2009, 2:401-408.
78. Rask-Madsen C., King G.L. Mechanisms of disease: endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 2007, 3:46-56.
79. Colwell J.A., Nesto R.W. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003, 26:2181-2188.
80. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease: the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1997, 96:1761-1769. [see comments].
81. BARI Investigators The final 10-year follow-up results from the BARI randomized trial. JAm Coll Cardiol 2007, 49:1600-1606.
82. Hlatky M.A., Boothroyd D.B., Bravata D.M., et al. Coronary artery bypass surgery compared with percutaneous coronary interventions for multivessel disease: a collaborative analysis of individual patient data from ten randomised trials. Lancet 2009, 373:1190-1197.
83. Hlatky M.A. Compelling evidence for coronary-bypass surgery in patients with diabetes. NEngl J Med 2012, 367:2437-2438.
84. Mohr F.W., Morice M.C., Kappetein A.P., et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet 2013, 381:629-638.
85. Kappetein A.P., Head S.J., Morice M.C., et al. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg 2013, 43:1006-1013.
86. Kapur A., Hall R., Malik I., et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. JAm Coll Cardiol 2010, 55:432-440.
87. Farkouh M.E., Domanski M., Sleeper L.A., et al. Strategies for multivessel revascularization in patients with diabetes. NEngl J Med 2012, 367:2375-2384.
88. Gum P., O'Keefe J.J., Borkon A., et al. Bypass surgery versus coronary angioplasty for revascularization of treated diabetic patients. Circulation 1997, 96:II7-II10.
89. Detre K.M., Lombardero M.S., Brooks M.M., et al. The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. NEngl J Med 2000, 342:989-997.
90. Kip K.E., Alderman E.L., Bourassa M.G., et al. Differential influence of diabetes mellitus on increased jeopardized myocardium after initial angioplasty or bypass surgery: bypass angioplasty revascularization investigation. Circulation 2002, 105:1914-1920.
91. Schwartz L., Kip K.E., Frye R.L., et al. Coronary bypass graft patency in patients with diabetes in the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 2002, 106:2652-2658.
92. Hoogwerf B.J., Waness A., Cressman M., et al. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial. Diabetes 1999, 48:1289-1294.
93. Aronson D., Edelman E.R. Role of CABG in the management of obstructive coronary arterial disease in patients with diabetes mellitus. Curr Opin Pharmacol 2012, 12:134-141.
94. Hwang H.Y., Choi J.S., Kim K.B. Diabetes does not affect long-term results after total arterial off-pump coronary revascularization. Ann Thorac Surg 2010, 90:1180-1186.
95. Kinoshita T., Asai T., Nishimura O., et al. Off-pump bilateral versus single skeletonized internal thoracic artery grafting in patients with diabetes. Ann Thorac Surg 2010, 90:1173-1179.
96. Pevni D., Uretzky G., Mohr A., et al. Routine use of bilateral skeletonized internal thoracic artery grafting: long-term results. Circulation 2008, 118:705-712.
97. Nakano J., Okabayashi H., Hanyu M., et al. Risk factors for wound infection after off-pump coronary artery bypass grafting: should bilateral internal thoracic arteries be harvested in patients with diabetes?. JThorac Cardiovasc Surg 2008, 135:540-545.
98. Saso S., James D., Vecht J.A., et al. Effect of skeletonization of the internal thoracic artery for coronary revascularization on the incidence of sternal wound infection. Ann Thorac Surg 2010, 89:661-670.
99. Kinoshita T., Asai T., Suzuki T., et al. Off-pump bilateral versus single skeletonized internal thoracic artery grafting in high-risk patients. Circulation 2011, 124:S130-S134.
100. Roffi M., Angiolillo D.J., Kappetein A.P. Current concepts on coronary revascularization in diabetic patients. Eur Heart J 2011, 32:2748-2757.
101. Choudhary B.P., Antoniades C., Brading A.F., et al. Diabetes mellitus as a predictor for radial artery vasoreactivity in patients undergoing coronary artery bypass grafting. JAm Coll Cardiol 2007, 50:1047-1053.
102. Goldman S., Sethi G.K., Holman W., et al. Radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: a randomized trial. JAMA 2011, 305:167-174.
103. Young L.H., Wackers F.J., Chyun D.A., et al. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. JAMA 2009, 301:1547-1555.
104. Chaitman B.R., Hardison R.M., Adler D., et al. The bypass angioplasty revascularization investigation 2 diabetes randomized trial of different treatment strategies in type 2 diabetes mellitus with stable ischemic heart disease: impact of treatment strategy on cardiac mortality and myocardial infarction. Circulation 2009, 120:2529-2540.
105. Patel M.R., Dehmer G.J., Hirshfeld J.W., et al. ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for coronary revascularization: a report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography. JAm Coll Cardiol 2009, 53:530-553.
106. Aronson D., Edelman E.R. Revascularization for coronary artery disease in diabetes mellitus: angioplasty, stents and coronary artery bypass grafting. Rev Endocr Metab Disord 2010, 11:75-86.
107. Banning A.P., Westaby S., Morice M.C., et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. JAm Coll Cardiol 2010, 55:1067-1075.
108. Onuma Y., Wykrzykowska J.J., Garg S., et al. 5-year follow-up of coronary revascularization in diabetic patients with multivessel coronary artery disease: insights from ARTS (Arterial Revascularization Therapy Study)-II and ARTS-I trials. JACC Cardiovasc Interv 2011, 4:317-323.
109. Wijns W., Kolh P., Danchin N., et al. Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2010, 31:2501-2555.
110. Kooy A., de Jager J., Lehert P., et al. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med 2009, 169:616-625.
111. Engler R.L., Yellon D.M. Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease. Time for reconsideration. Circulation 1996, 94:2297-2301. [see comments].
112. Singh S., Bhat J., Wang P.H. Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus. Curr Cardiol Rep 2013, 15:327.
113. Marx N., Wohrle J., Nusser T., et al. Pioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patients. Circulation 2005, 112:2792-2798.
114. Takagi T., Akasaka T., Yamamuro A., et al. Troglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with non-insulin dependent diabetes mellitus: a serial intravascular ultrasound study. JAm Coll Cardiol 2000, 36:1529-1535.
115. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 2003, 108:2941-2948.
116. McMurray J.J., Gerstein H.C., Holman R.R., et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol 2014, [Epub ahead of print]. 10.1016/S2213-8587(14)70031-2.
117. Chiasson J.L., Josse R.G., Gomis R., et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003, 290:486-494.
118. Fox C.S. Weighty matters: balancing weight gain with cardiovascular risk among patients with type 1 diabetes mellitus on intensive insulin therapy. Circulation 2013, 127:157-159.
119. Ismail-Beigi F. Clinical practice. Glycemic management of type 2 diabetes mellitus. NEngl J Med 2012, 366:1319-1327.